Date published: 2026-1-7

1-800-457-3801

SCBT Portrait Logo
Seach Input

Erlotinib, Free Base (CAS 183321-74-6)

0.0(0)
Write a reviewAsk a question

See product citations (42)

Alternate Names:
Tarceva; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
Application:
Erlotinib, Free Base is a tyrosine kinase inhibitor
CAS Number:
183321-74-6
Purity:
≥98%
Molecular Weight:
393.44
Molecular Formula:
C22H23N3O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

Erlotinib, Free Base, is the free base form of erlotinib hydrochloride (sc-202154), a small molecule EGFR/HER-1 (human epidermal growth factor receptor) tyrosine kinase reversible inhibitor. EGFR and tyrosine kinases are involved in the growth and spread of cancer cells. Erlotinib also inhibits the growth of new blood vessels, which is important for the growth and spread of tumors. Furthermore, it may act to reduce the levels of certain proteins involved in cell proliferation and survival, such as Bcl-2, VEGF, and MMP-9. In vitro scientific research applications involve the use of erlotinib in cell culture systems to study its effects on cell proliferation, migration, and other cellular activities.


Erlotinib, Free Base (CAS 183321-74-6) References

  1. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.  |  Greenhalgh, J., et al. 2015. Health Technol Assess. 19: 1-134. PMID: 26134145
  2. Erlotinib for the treatment of brain metastases in non-small cell lung cancer.  |  Brower, JV. and Robins, HI. 2016. Expert Opin Pharmacother. 17: 1013-21. PMID: 26967582
  3. Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.  |  Tagliamento, M., et al. 2018. Expert Opin Pharmacother. 19: 2055-2062. PMID: 30392436
  4. An Erlotinib gold(I) conjugate for combating triple-negative breast cancer.  |  Ortega, E., et al. 2020. J Inorg Biochem. 203: 110910. PMID: 31683128
  5. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.  |  Leighl, NB., et al. 2020. Eur J Cancer. 125: 49-57. PMID: 31838405
  6. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer.  |  Bao, K., et al. 2021. Clin Ther. 43: 1107-1115. PMID: 34059328
  7. Erlotinib complexation with randomly methylated β-cyclodextrin improves drug solubility, intestinal permeability, and therapeutic efficacy in non-small cell lung cancer.  |  Erdoğar, N., et al. 2021. Pharm Dev Technol. 26: 797-806. PMID: 34219578
  8. Erlotinib-Induced Cardiomyopathy in a Patient with Metastatic Non-Small Cell Lung Cancer.  |  Nagashio, K., et al. 2021. Int Heart J. 62: 1171-1175. PMID: 34497169
  9. Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib.  |  Bagherian, A., et al. 2021. Food Funct. 12: 10926-10937. PMID: 34647945
  10. Erlotinib-induced leukoencephalopathy mimicking CO intoxication.  |  Noh, SM. and Kang, HG. 2022. Neurol Sci. 43: 2111-2113. PMID: 35029752
  11. Stability and Formulation of Erlotinib in Skin Creams.  |  Nguyen, D., et al. 2022. Molecules. 27: PMID: 35164335
  12. Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.  |  Choi, YS., et al. 2022. Endocr Relat Cancer. 29: 307-319. PMID: 35343921
  13. Antioxidant activity of erlotinib and gefitinib: theoretical and experimental insights.  |  K P, SH., et al. 2022. Free Radic Res. 56: 196-208. PMID: 35514158
  14. Preparation of radiolabeled erlotinib analogues and analysis of the effect of linkers.  |  Jain, A., et al. 2022. Bioorg Med Chem Lett. 76: 128995. PMID: 36152732
  15. Tumor Cell-Specific Retention and Photodynamic Action of Erlotinib-Pyropheophorbide Conjugates.  |  Tracy, EC., et al. 2022. Int J Mol Sci. 23: PMID: 36232384

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

Erlotinib, Free Base, 500 mg

sc-396113
500 mg
$87.00

Erlotinib, Free Base, 1 g

sc-396113A
1 g
$135.00

Erlotinib, Free Base, 5 g

sc-396113B
5 g
$293.00

Erlotinib, Free Base, 10 g

sc-396113C
10 g
$505.00

Erlotinib, Free Base, 100 g

sc-396113D
100 g
$3827.00